SSG
EPRS

Summit Securities Group’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Summit Securities Group’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100
Closed – – 532
2015
Q3 		$0 Buy
+100
New +$587 ﹤0.01% 644

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Summit Securities Group's EPRS Position: Q4 2015 in Review

Summit Securities Group sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q4 2015, closing a stake of 100 shares.

Summit Securities Group first reported a position in EPRS in Q3 2015 and held it in 1 quarter. The position peaked at $0 in Q3 2015. 45 funds tracked by Wall St. Rank hold EPRS as of Q4 2015.

  • Summit Securities Group reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q4 2015 after selling out during the quarter.
  • Summit Securities Group sold 100 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q4 2015.
  • Summit Securities Group first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q3 2015 and held it in 1 quarter.
  • Summit Securities Group's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $0 in Q3 2015.
  • 45 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q4 2015.

Based on Summit Securities Group's 13F filing for Q4 2015, filed 11 Feb 2016.